Neuroscience
A Reuters report:
-
Anthony H. Risser | neuroscience | neuropsychology | brain
- Business World: Myriad Genetics, Flurizan (mpc-7869), And Alzheimer Disease
From the AP, via Yahoo! News: Largest-Ever Alzheimer's Drug Trial Begins By PAUL ELIAS, AP Biotechnology Writer Sun Mar 12, 6:58 AM ET SAN FRANCISCO - It's tragedy enough that Pat Williams' mother...
- Business World: New Insomnia Meds, Including Takeda's Ramelteon (rozerem, Tak-375)
A brief overview to some of the anticipated insomnia medications trending from this year to next, this is from a recent Reuters report, as published on the International Herald Tribune website:New entries shake insomnia market's slumber Reuters ...
- Cylert
From Reuters: Abbott Says Withdrawing Attention Deficit Drug 24 March 2005 Health - Reuters WASHINGTON (Reuters) - Abbott Laboratories Inc. said Thursday it was halting sales of a 30-year-old attention deficit drug that a consumer group complained was...
- Lunesta (eszopiclone)
With New Sleeping Pill, New Acceptability? By ANDREW POLLACK The New York Times 17 December 2004 Is it a wake-up call for the sleeping pill market? With Wednesday's approval of Sepracor's new drug, Lunesta, a taboo in the use of sleeping...
- Forthcoming Meeting: Exanta And Stroke Prevention
Reuters reports that the FDA will be holding a meeting tomorrow to discuss Exanta and its use as an anti-stroke medication. Here is the text of the FDA announcement about this meeting: FDA Announcement and the text of the FDA Briefing Note: FDA Briefing...
Neuroscience
Business World: Takeda's Ramelteon (TAK-375)
A Reuters report:
Takeda may extend sleeping pill's use for Alzheimer's[ ... Read the full report ...]
Mon Jul 11, 2005 05:41 AM ET
TOKYO, July 11 (Reuters) - Japan's biggest drug maker, Takeda Pharmaceutical Co. Ltd ... said on Monday it is on track to release a sleeping pill as early as September in the United States and may extend its use to treat Alzheimer's disease and other illnesses.
The Osaka-based drug maker plans to launch its insomnia drug Ramelteon in the U.S. market in September or October, marking its entry into the central nervous system disease segment, Takeda President Yasuchika Hasegawa told an analysts' meeting.
-
Anthony H. Risser | neuroscience | neuropsychology | brain
- Business World: Myriad Genetics, Flurizan (mpc-7869), And Alzheimer Disease
From the AP, via Yahoo! News: Largest-Ever Alzheimer's Drug Trial Begins By PAUL ELIAS, AP Biotechnology Writer Sun Mar 12, 6:58 AM ET SAN FRANCISCO - It's tragedy enough that Pat Williams' mother...
- Business World: New Insomnia Meds, Including Takeda's Ramelteon (rozerem, Tak-375)
A brief overview to some of the anticipated insomnia medications trending from this year to next, this is from a recent Reuters report, as published on the International Herald Tribune website:New entries shake insomnia market's slumber Reuters ...
- Cylert
From Reuters: Abbott Says Withdrawing Attention Deficit Drug 24 March 2005 Health - Reuters WASHINGTON (Reuters) - Abbott Laboratories Inc. said Thursday it was halting sales of a 30-year-old attention deficit drug that a consumer group complained was...
- Lunesta (eszopiclone)
With New Sleeping Pill, New Acceptability? By ANDREW POLLACK The New York Times 17 December 2004 Is it a wake-up call for the sleeping pill market? With Wednesday's approval of Sepracor's new drug, Lunesta, a taboo in the use of sleeping...
- Forthcoming Meeting: Exanta And Stroke Prevention
Reuters reports that the FDA will be holding a meeting tomorrow to discuss Exanta and its use as an anti-stroke medication. Here is the text of the FDA announcement about this meeting: FDA Announcement and the text of the FDA Briefing Note: FDA Briefing...